Altered leptin, adiponectin, resistin and ghrelin secretion may represent an intrinsic polycystic ovary syndrome abnormality

References

• Rotterdam ESHRE/ASRM‐sponsored PCOS Consensus Workshop Group. Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome (PCOS). Hum Reprod. 2004;19:41–47.
   PubMed Web of Science ®Google Scholar
• Azziz R, Carmina E, Dewailly D, et al. Positions statement: criteria for defining polycystic ovary syndrome as a predominantly hyperandrogenic syndrome: an Androgen Excess Society guideline. J Clin Endocrinol Metab. 2006;91:4237–4245.
   PubMed Web of Science ®Google Scholar
• Teede H, Deeks A, Moran L. Polycystic ovary syndrome: a complex condition with psychological, reproductive and metabolic manifestations that impacts on health across the lifespan. BMC Med. 2010;8:41.
   PubMed Web of Science ®Google Scholar
• Diamanti-Kandarakis E, Dunaif A. Insulin resistance and the polycystic ovary syndrome revisited: an update on mechanisms and implications. Endocr Rev. 2012;33:981–1030.
   PubMed Web of Science ®Google Scholar
• Moran LJ, Misso ML, Wild RA, et al. Impaired glucose tolerance, type 2 diabetes and metabolic syndrome in polycystic ovary syndrome: a systematic review and meta-analysis. Hum Reprod Update. 2010;16:347–363.
   PubMed Web of Science ®Google Scholar
• Randeva HS, Tan BK, Weickert MO, et al. Cardiometabolic aspects of the polycystic ovary syndrome. Endocr Rev. 2012;33:812–841.
   PubMed Web of Science ®Google Scholar
• Carmina E, Bucchieri S, Esposito A, et al. Abdominal fat quantity and distribution in women with polycystic ovary syndrome and extent of its relation to insulin resistance. J Clin Endocrinol Metab. 2007;92:2500–2505.
   PubMed Web of Science ®Google Scholar
• Baldani DP, Skrgatic L, Goldstajn MS, et al. Clinical and biochemical characteristics of polycystic ovary syndrome in Croatian population. Coll Antropol. 2012;36:1413–1418.
   PubMedGoogle Scholar
• Vermeulen A, Verdonck L, Kaufman JM. A critical evaluation of simple methods for the estimation of free testosterone in serum. J Clin Endocrinol Metab. 1999;84:3666–3672.
   PubMed Web of Science ®Google Scholar
• Matthews DR, Hosker JP, Rudenski AS, et al. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia. 1985;28:412–419.
   PubMed Web of Science ®Google Scholar
• Pehlivanov B, Mitkov M. Serum leptin levels correlate with clinical and biochemical indices of insulin resistance in women with polycystic ovary syndrome. Eur J Contracept Reprod Health Care. 2009;14:153–159.
   PubMed Web of Science ®Google Scholar
• Remsberg KE, Talbott EO, Zborowski JV, et al. Evidence for competing effects of body mass, hyperinsulinemia, insulin resistance, and androgens on leptin levels among lean, overweight, and obese women with polycystic ovary syndrome. Fertil Steril. 2002;78:479–486.
   PubMed Web of Science ®Google Scholar
• Escobar-Morreale HF, Villuendas G, Botella CJI, et al. Adiponectin and resistin in PCOS: a clinical, biochemical and molecular genetic study. Hum Reprod. 2006;21:2257–2265.
   PubMed Web of Science ®Google Scholar
• Glintborg D, Andersen M, Hagen C, et al. Evaluation of metabolic risk markers in polycystic ovary syndrome (PCOS). Adiponectin, ghrelin, leptin and body composition in hirsute PCOS patients and controls. Eur J Endocrinol. 2006;155:337–345.
   PubMed Web of Science ®Google Scholar
• Ducluzeau PH, Cousin P, Malvoisin E, et al. Glucose-to-insulin ratio rather than sex hormone-binding globulin and adiponectin levels is the best predictor of insulin resistance in nonobese women with polycystic ovary syndrome. J Clin Endocrinol Metab. 2003;88:3626–3631.
   PubMed Web of Science ®Google Scholar
• Sieminska L, Marek B, Kos-Kudla B, et al. Serum adiponectin in women with polycystic ovarian syndrome and its relation to clinical, metabolic and endocrine parameters. J Endocrinol Invest. 2004;27:528–534.
   PubMed Web of Science ®Google Scholar
• Toulis KA, Goulis DG, Farmakiotis D, et al. Adiponectin levels in women with polycystic ovary syndrome: a systematic review and a meta-analysis. Hum Reprod Update. 2009;15:297–307.
   PubMed Web of Science ®Google Scholar
• Arikan S, Bahceci M, Tuzcu A, et al. Serum resistin and adiponectin levels in young non-obese women with polycystic ovary syndrome. Gynecol Endocrinol. 2010;26:161–166.
   PubMed Web of Science ®Google Scholar
• Cassar S, Teede HJ, Harrison CL, et al. Biomarkers and insulin sensitivity in women with polycystic ovary syndrome: characteristics and predictive capacity. Clin Endocrinol. 2015;83:50–58.
   PubMed Web of Science ®Google Scholar
• O'Connor A, Phelan N, Tun TK, et al. High-molecular-weight adiponectin is selectively reduced in women with polycystic ovary syndrome independent of body mass index and severity of insulin resistance. J Clin Endocrinol Metab. 2010;95:1378–1385.
   PubMed Web of Science ®Google Scholar
• Li S, Huang X, Zhong H, et al. Low circulating adiponectin levels in women with polycystic ovary syndrome: an updated meta-analysis. Tumor Biol. 2014;35:3961–3973.
   PubMed Web of Science ®Google Scholar
• Yilmaz M, Bukan N, Demirci H, et al. Serum resistin and adiponectin levels in women with polycystic ovary syndrome. Gynecol Endocrinol. 2009;25:246–252.
   PubMed Web of Science ®Google Scholar
• Barber TM, Casanueva FF, Karpe F, et al. Ghrelin levels are suppressed and show a blunted response to oral glucose in women with polycystic ovary syndrome. Eur J Endocrinol. 2008;158:511–516.
   PubMed Web of Science ®Google Scholar
• Panidis D, Farmakiotis D, Koliakos G, et al. Comparative study of plasma ghrelin levels in women with polycystic ovary syndrome, in hyperandrogenic women and in normal controls. Hum Reprod. 2005;20:2127–2132.
   PubMed Web of Science ®Google Scholar